.. .. References, , p.33

.. .. Serment-d'hippocrate, , p.36

.. .. Conclusion,

Y. Nilssen, T. E. Strand, L. Fjellbirkeland, K. Bartnes, and B. Møller, Lung cancer survival in Norway, vol.47, pp.275-287, 1997.

R. Meza, C. Meernik, J. Jeon, and M. L. Cote, Lung Cancer Incidence Trends by Gender, Race and Histology in the United States, PLOS ONE, vol.10, p.121323, 1973.

M. Grivaux, B. Duvert, P. Ferrer-lopez, S. Hominal, E. Goarant et al., One-year survival improvement in lung cancer in France. Results of the prospective real life studies, Rev Pneumol Clin, vol.72, pp.163-170, 2016.

M. B. Schabath, A. Nguyen, P. Wilson, K. R. Sommerer, Z. J. Thompson et al., Temporal trends from 1986 to 2008 in overall survival of small cell lung cancer patients, Lung Cancer, vol.86, pp.14-21, 2014.

P. Goldstraw, K. Chansky, and J. Crowley, The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer, Journal of Thoracic Oncology, vol.11, pp.39-51, 2016.

B. M. Fischer and J. Mortensen, The Future in Diagnosis and Staging of Lung Cancer: Positron Emission Tomography, Respiration, vol.73, pp.267-276, 2006.

S. Bishnoi, K. Pittman, M. Colbeck, A. Townsend, J. Hardingham et al., Small cell lung cancer: patterns of care and their influence on survival -25 years experience of a single Australian oncology unit, Asia Pac J Clin Oncol, vol.7, pp.252-257, 2011.

A. Rossi, M. D. Maio, P. Chiodini, R. M. Rudd, H. Okamoto et al., Carboplatin-or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data, Journal of Clinical Oncology, vol.30, pp.1692-1698, 2012.

M. Früh, D. De-ruysscher, S. Popat, L. Crinò, S. Peters et al., Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, ESMO Guidelines Working Group, vol.24, pp.99-105, 2013.

B. Slotman, C. Faivre-finn, G. Kramer, E. Rankin, M. Snee et al., Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer, New England Journal of Medicine, vol.357, pp.664-672, 2007.

J. Pawel, J. H. Schiller, F. A. Shepherd, S. Z. Fields, J. P. Kleisbauer et al., Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer, J. Clin. Oncol, vol.17, pp.658-667, 1999.

H. Nagy-mignotte, P. Guillem, L. Vignoud, M. Coudurier, A. Vesin et al., Outcomes in recurrent small-cell lung cancer after one to four chemotherapy lines: A retrospective study of 300 patients, Lung Cancer, vol.78, pp.112-120, 2012.

M. M. Oken, R. H. Creech, D. C. Tormey, J. Horton, T. E. Davis et al., Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am. J. Clin. Oncol, vol.5, pp.649-655, 1982.

E. A. Eisenhauer, P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent et al., New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, pp.228-247, 2009.

A. Kurup and N. H. Hanna, Treatment of small cell lung cancer, Critical Reviews in Oncology/Hematology, vol.52, pp.117-126, 2004.

C. Dayen, D. Debieuvre, O. Molinier, O. Raffy, F. Paganin et al., New insights into stage and prognosis in small cell lung cancer: an analysis of 968 cases, Journal of Thoracic Disease, vol.9, pp.5101-5111, 2017.

A. Khakwani, A. L. Rich, L. J. Tata, H. A. Powell, R. A. Stanley et al., Small-Cell Lung Cancer in England: Trends in Survival and Chemotherapy Using the National Lung Cancer Audit, PLoS ONE, vol.9, p.89426, 2014.

M. J. Aarts, J. G. Aerts, B. E. Van-den-borne, B. Biesma, V. E. Lemmens et al., Comorbidity in Patients With Small-Cell Lung Cancer: Trends and Prognostic Impact, vol.16, pp.282-291, 2015.

M. Torres-durán, A. Ruano-ravina, K. T. Kelsey, I. Parente-lamelas, M. Provencio et al., Barros-Dios, Small cell lung cancer in never-smokers, European Respiratory Journal, vol.47, pp.947-953, 2016.

M. Behera, C. Ragin, S. Kim, R. N. Pillai, Z. Chen et al., Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between, Small Cell Lung Cancer in SEER-Medicare, vol.122, pp.50-60, 1985.

K. Gokmen-aktas and . Tulay, Survival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study, OncoTargets and Therapy, p.1921, 2016.

Z. Song, L. Shao, B. Lin, and Y. Zhang, Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis, Clinical and Translational Oncology, vol.15, pp.843-848, 2013.

D. Paul-carbone, Efficacy and safety of rovalpituzumab tesirine in patients With DLL3-expressing, ? 3rd line small cell lung cancer: Results from the phase 2 TRINITY study